Pick up a strip of tablets at a pharmacy in Karachi or Lahore this month and look at the outer carton. If the pack was made or imported after the new deadline, it carries something Pakistani medicine packs have never had to carry before: a small square 2-D barcode with a serial number that belongs to that one pack alone. Scan it, and the pack is supposed to tell you what it is, when it expires, and whether it is genuine.

The Drug Regulatory Authority of Pakistan, DRAP, has made 2-D barcoding and serialisation mandatory for pharmaceutical products under its Pharmaceutical Track and Trace System. Reporting by ARY News this week put the dividing line at 9 October: products manufactured locally or imported on or after that date must carry the code, while batches made or imported before it are exempt and can still be imported, distributed and sold. That exemption matters. It means two packs of the same medicine can sit side by side on a shelf for months, one coded and one not, and both can be perfectly legal.

DRAP's own website carries the paper trail for the imported side of the trade. Its news updates for 7 September 2026 list a notification titled Mandatory Compliance with 2-D Barcode and Serialisation Requirements for Imported Finished Pharmaceutical Products, alongside a corrigendum to it, and a separate notice closing the deadline for data validation on DRAP's eApp software so company records could be integrated with the track and trace system. The same site shows the authority running training sessions on the online track and trace system through late September for industry groups in Punjab, Sindh and Balochistan, Khyber Pakhtunkhwa, and Islamabad, Rawalpindi and Azad Jammu and Kashmir. Regulators do not run that kind of training calendar for a rule they intend to leave on paper.

What is actually printed on the pack

The code is a GS1 DataMatrix, the compact square format that can hold more information than the striped barcode on a grocery item. Reporting on the technical requirements describes each pack carrying a unique, randomly generated serial number of 12 to 20 characters, encoded in the matrix alongside the product's global trade item number, its batch number and its expiry date. Four pieces of information, one scan.

The serial is the part that changes the game. A batch number is shared by thousands of packs. A serial number is not. When every pack has its own identity, a regulator can follow that pack from the factory gate or the port, through distributors, to the pharmacy shelf. A recall stops being a general announcement and becomes a list of specific packs. A pack that shows up in two cities at once, or a serial that was never issued, flags itself.

For the person buying the medicine, the promise is simpler. DRAP has said consumers will be able to scan the code with a smartphone to verify authenticity, and the federal health ministry, announcing cabinet approval of the system earlier this year, said buyers would be able to check a medicine's expiry date, its official price and its verification status. Anyone who has ever squinted at a faded expiry stamp in a dim pharmacy will understand why that matters. So will anyone who has read our reporting on rabies treatment in Sindh, where the quality of what reaches a patient in time is the whole story.

Why Pakistan is doing this now

Counterfeit and substandard medicines are not an abstract risk here. DRAP's own site carries a steady stream of recall alerts and safety notices for products that failed quality tests, and the authority says the new system is aimed squarely at spurious, falsified, counterfeit and unregistered medicines. The legal route ran through the federal cabinet, which approved amendments to the Drugs Labelling and Packing Rules, 1978, the rules that govern what must appear on a medicine pack. Health Minister Syed Mustafa Kamal described the cabinet decision as a historic step towards eradicating fake and substandard drugs, and said that for the first time medicines in the country would be digitally traceable and verifiable.

There is also a paperwork deadline hiding behind the packaging one. DRAP closed the window for companies to correct product and licence data on its eApp portal in late August, ahead of the September notification on data validation. The logic is hard to argue with: a verification system is only as good as the database behind it, and a scan that checks a pack against wrong records helps nobody. Companies whose data was inaccurate when the window closed now have to live with that record until DRAP reopens corrections.

Industry has been consulted rather than ambushed, at least on paper. DRAP says it held consultations with the Pakistan Pharmaceutical Manufacturers' Association, the Pharma Bureau and medicine importers to prepare for implementation, and the rollout is phased, starting at the secondary packaging level, the outer carton a customer actually holds. Warnings have gone out too. The authority has directed manufacturers and importers to meet the technical requirements and says legal action will follow for those who violate the regulations.

What the rule covers, and what it leaves out

Scope is where early reporting got sloppy, so it is worth being precise. The requirement covers allopathic medicines, including biological products, for human and veterinary use. Your dog's medicine is in. Your own prescription is in.

But not everything on a pharmacy shelf is in. Alternative medicines, nutraceuticals, medical devices, medical gases and radiopharmaceuticals sit outside the stated scope of the serialisation requirement. A herbal tonic with no code is not automatically an illegal product, and a medical device without a DataMatrix has not broken this rule. Readers who follow our coverage of nutrition and immune health will know how large that supplement shelf has become, and how different its rules are.

The pre-deadline exemption cuts the other way as well. Stock manufactured or imported before the October date remains lawful to sell, so the absence of a code on an older batch proves nothing by itself. What should raise a question is a newly manufactured pack with no code, a code that does not scan, or a scan result that does not match the medicine in your hand. Those are the checks worth doing, and worth reporting to the pharmacy and to DRAP if the answers do not line up.

What changes at the pharmacy counter

For pharmacies, the shift is operational. Stock arriving from now on should be checked for codes at intake, and staff will field the first wave of customer questions from people who have scanned a pack and want to know what the result means. For patients, the habit to build is small and quick: scan the carton before you pay, confirm the name and strength match what the doctor prescribed, and read the expiry date off the verification result rather than trusting a smudged stamp.

How the check works, in practice, is deliberately ordinary. The code sits on the outer carton. A phone camera reads it. The result pulls the pack's registered identity from the track and trace database: product name, manufacturer or importer, batch, expiry, and the pack's own serial. If the serial was never issued, or it has already been scanned as sold somewhere else, that is the moment to stop and ask questions. No special app knowledge is needed beyond being able to scan a code, a skill Pakistan's shoppers have already learned from mobile payments.

The phasing deserves a word too, because it explains the mixed shelves. The first phase covers secondary packaging, the carton, for locally manufactured and imported products alike. Older stock keeps its exemption until it sells through. That is a slower, less dramatic transition than a single hard switch-off date, and it is also the only realistic one for a supply chain that runs from multinational importers down to a single-counter pharmacy in a small town. DRAP's late-September training calendar, spread across every province, was built for exactly that long tail of businesses.

There is a quieter benefit buried in the system that may outlast the counterfeit fight. Recall speed. When a batch fails a quality test today, word travels through notices, inspectors and pharmacy ledgers, and packs can stay on shelves longer than anyone intends. With serialised packs feeding a central system, a recall can name the exact batch, and in time the exact packs, that need to come back. For a country that has lived through contaminated-medicine tragedies in past decades, that speed is not a technical nicety. It is the difference between a warning and a rescue.

None of this fixes the wider problems on their own. A barcode cannot make an out-of-stock medicine appear, and it cannot lower a price. The pressures described in our piece on longer lives spent in poorer health will still be there. What the serial number does is narrower and, for that reason, believable: it gives every pack an identity that is hard to borrow, and it gives patients a way to check that identity themselves instead of taking a shelf's word for it.

Expect a messy middle period. Shelves will hold a mix of coded and uncoded stock while the exempt batches work their way through the system, and early scan results will only be as reliable as the data companies filed before the August freeze. Judge the system in a year, when the uncoded stock has cleared and scanning has become as routine as checking a price. If it gets there, Pakistan will have something it has never had: a medicine supply chain that can be audited pack by pack, by the regulator and by the patient alike.

This article is general information about a regulatory change, not medical advice. If you are concerned about a medicine you have bought, speak to your pharmacist or doctor.